Michael A Bowes1,2, Rose A Maciewicz3,4, John C Waterton3,4, David J Hunter3,4, Philip G Conaghan3,4. 1. From the Imorphics; Biomedical Imaging Institute, Manchester Academic Health Sciences Centre, University of Manchester, Manchester; Respiratory, Inflammation, Autoimmunity Innovative Medicines and Early Development (IMED), AstraZeneca, Cambridge; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK; Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Sydney, Australia; Rheumatology Department, Royal North Shore Hospital, St. Leonards, Australia. mike@imorphics.com. 2. M.A. Bowes, PhD, Imorphics; R.A. Maciewicz, PhD, Chief Scientist, Respiratory, Inflammation, Autoimmunity IMED, AstraZeneca; J.C. Waterton, PhD, Professor of Translational Imaging, Biomedical Imaging Institute, Manchester Academic Health Sciences Centre, University of Manchester; D.J. Hunter, PhD, Florance and Cope Chair of Rheumatology, Professor of Medicine, Institute of Bone and Joint Research, Kolling Institute, University of Sydney, and Rheumatology Department, Royal North Shore Hospital; P.G. Conaghan, MBBS, PhD, FRACP, FRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit. mike@imorphics.com. 3. From the Imorphics; Biomedical Imaging Institute, Manchester Academic Health Sciences Centre, University of Manchester, Manchester; Respiratory, Inflammation, Autoimmunity Innovative Medicines and Early Development (IMED), AstraZeneca, Cambridge; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK; Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Sydney, Australia; Rheumatology Department, Royal North Shore Hospital, St. Leonards, Australia. 4. M.A. Bowes, PhD, Imorphics; R.A. Maciewicz, PhD, Chief Scientist, Respiratory, Inflammation, Autoimmunity IMED, AstraZeneca; J.C. Waterton, PhD, Professor of Translational Imaging, Biomedical Imaging Institute, Manchester Academic Health Sciences Centre, University of Manchester; D.J. Hunter, PhD, Florance and Cope Chair of Rheumatology, Professor of Medicine, Institute of Bone and Joint Research, Kolling Institute, University of Sydney, and Rheumatology Department, Royal North Shore Hospital; P.G. Conaghan, MBBS, PhD, FRACP, FRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit.
Abstract
OBJECTIVE: To analyze the 3-D bone area from an osteoarthritis (OA) cohort demonstrating no change in cartilage thickness. METHODS: Twenty-seven women with painful medial knee OA had magnetic resonance images at 0, 3, and 6 months. Images were analyzed using active appearance models. RESULTS: At 3 and 6 months, the mean change in medial femoral bone area was 0.34% (95% CI 0.04-0.64) and 0.61% (95% CI 0.32-0.90), respectively. Forty-one percent of the subjects had progression greater than the smallest detectable difference at 6 months. CONCLUSION: In this small cohort at high risk of OA progression, bone area changed at 3 and 6 months when cartilage morphometric measures did not.
OBJECTIVE: To analyze the 3-D bone area from an osteoarthritis (OA) cohort demonstrating no change in cartilage thickness. METHODS: Twenty-seven women with painful medial knee OA had magnetic resonance images at 0, 3, and 6 months. Images were analyzed using active appearance models. RESULTS: At 3 and 6 months, the mean change in medial femoral bone area was 0.34% (95% CI 0.04-0.64) and 0.61% (95% CI 0.32-0.90), respectively. Forty-one percent of the subjects had progression greater than the smallest detectable difference at 6 months. CONCLUSION: In this small cohort at high risk of OA progression, bone area changed at 3 and 6 months when cartilage morphometric measures did not.
Authors: Anke J Roelofs; Karolina Kania; Alexandra J Rafipay; Meike Sambale; Stephanie T Kuwahara; Fraser L Collins; Joanna Smeeton; Maxwell A Serowoky; Lynn Rowley; Hui Wang; René Gronewold; Chrysa Kapeni; Simón Méndez-Ferrer; Christopher B Little; John F Bateman; Thomas Pap; Francesca V Mariani; Joanna Sherwood; J Gage Crump; Cosimo De Bari Journal: Ann Rheum Dis Date: 2020-09-22 Impact factor: 19.103